DK2627346T3 - Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til anvendelse i behandling af uveitis - Google Patents

Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til anvendelse i behandling af uveitis Download PDF

Info

Publication number
DK2627346T3
DK2627346T3 DK11775734.4T DK11775734T DK2627346T3 DK 2627346 T3 DK2627346 T3 DK 2627346T3 DK 11775734 T DK11775734 T DK 11775734T DK 2627346 T3 DK2627346 T3 DK 2627346T3
Authority
DK
Denmark
Prior art keywords
seq
peptide
sequence
pro
jnk
Prior art date
Application number
DK11775734.4T
Other languages
English (en)
Inventor
Catherine Deloche
Claire Abadie
Jean-Marc Combette
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/006284 external-priority patent/WO2012048721A1/en
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Application granted granted Critical
Publication of DK2627346T3 publication Critical patent/DK2627346T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Claims (10)

1. Kimært (poly)peptid omfattende et JNK-inhibitor(poly)peptid til anvendelse i behandling af uveitis, hvor det kimære (poly)peptid består af eller omfatter den samlede D-aminosyresekvens ifølge SEQ ID NO: 11 eller et fragment eller en variant deraf med en sekvenssimilaritet på mindst 90 % med den samlede D-aminosyresekvens ifølge SEQ ID NO: 11.
2. Kimært (poly)peptid til anvendelse ifølge krav 1, hvor det kimære (poly)peptid består af aminosyresekvensen ifølge SEQ ID NO: 11.
3. Kimært (poly)peptid til anvendelse ifølge krav 1 eller 2 til behandling af anterior, intermediær eller posterior uveitis.
4. Kimært (poly)peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor JNK-inhibitor(poly)peptidet binder sig til c-jun-aminoterminal kinase (JNK).
5. Kimært (poly)peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor JNK-inhibitor(poly)peptidet hæmmer aktivering af mindst én JNK-rettet transkrip-tionsfaktor, når JNK-inhibitor(poly)peptidet er til stede i en JNK-udtrykkende celle, hvor den JNK-rettede transkriptionsfaktor fortrinsvis er udvalgt fra gruppen bestående af c-Jun, ATF2 og Elkl og/eller ændrer en JNK-virkning, når peptidet er til stede i en JNK-udtrykkende celle.
6. Farmaceutisk sammensætning til brug i behandling af uveitis omfattende et kimært (poly)peptid bestående af eller omfattende den samlede D-aminosyresekvens ifølge SEQ ID NO: 11 eller et fragment eller en variant med en sekvenssimilaritet på mindst 90 % med den samlede D-aminosyresekvens ifølge SEQ ID NO: 11.
7. Farmaceutisk sammensætning til brug ifølge krav 6, yderligere omfattende et farmaceutisk acceptabelt bærestof, hjælpestof, buffer eller stabilisator.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, hvor bærestoffet er et flydende bærestof, fortrinsvis isotonisk saltvand eller pufret vandig opløsning.
9. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6 til 8, hvor den farmaceutiske sammensætning er til anvendelse i behandling af anterior, intermediær eller posterior uveitis.
10. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 6 til 9, hvor den farmaceutiske sammensætning skal indgives ad en indgiftsvej udvalgt fra gruppen bestående af parenterale veje, herunder intravenøst, intramuskulært, subkutant, intradermalt, transdermalt, enterale veje, herunder oralt, rektalt, topiske veje, herunder nasalt, intranasalt, andre veje, herunder epidermalt eller ved plasterindbringning, og lokal indgift til øjet, navnlig intravitrøs indgift, subkonjunktivisk indgift og/eller inddryp-ning.
DK11775734.4T 2010-10-14 2011-10-14 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til anvendelse i behandling af uveitis DK2627346T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/006284 WO2012048721A1 (en) 2010-10-14 2010-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2011000307 2011-01-25
PCT/EP2011/005172 WO2012048893A1 (en) 2010-10-14 2011-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

Publications (1)

Publication Number Publication Date
DK2627346T3 true DK2627346T3 (da) 2016-06-13

Family

ID=44862926

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11775734.4T DK2627346T3 (da) 2010-10-14 2011-10-14 Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til anvendelse i behandling af uveitis
DK14004427.2T DK2902035T3 (da) 2010-10-14 2011-10-14 Fremgangsmåder til behandling af muskeldystrofi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14004427.2T DK2902035T3 (da) 2010-10-14 2011-10-14 Fremgangsmåder til behandling af muskeldystrofi

Country Status (7)

Country Link
EP (2) EP2627346B1 (da)
CY (1) CY1120936T1 (da)
DK (2) DK2627346T3 (da)
ES (2) ES2688030T3 (da)
HK (2) HK1187266A1 (da)
PL (2) PL2902035T3 (da)
WO (1) WO2012048893A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206563A2 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3160489B9 (en) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
DE102016111708A1 (de) 2016-06-27 2017-12-28 Heiko Schmidt Gelenkanordnung, vorgefertigte Baugruppe sowie Verfahren zur Herstellung einer vorgefertigten Baugruppe einer Gelenkanordnung
CN108060223A (zh) * 2017-12-29 2018-05-22 北京泱深生物信息技术有限公司 Atf2基因的新应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DK0671923T3 (da) 1992-10-09 2001-08-13 Advanced Tissue Sciences Inc Leverreserveceller
CN1208438A (zh) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 转运蛋白及其应用
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
WO2008006046A1 (en) * 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
EP2415478A4 (en) * 2009-03-30 2013-01-16 Santen Pharmaceutical Co Ltd PROPHYLAXIS OR THERAPY AGENTS FOR KIDNEY DISEASES AND METHODS OF PREVENTING OR TREATING NURSE DISEASES, EACH OF THEM WITH A JNK (C-JUN-N-TERMINAL KINASE) -IMBING PEPTIDE, AND USE OF THE PEPTIDE

Also Published As

Publication number Publication date
PL2627346T3 (pl) 2016-11-30
CY1120936T1 (el) 2019-12-11
ES2575226T3 (es) 2016-06-27
HK1187266A1 (zh) 2014-04-04
EP2627346B1 (en) 2016-03-23
ES2688030T3 (es) 2018-10-30
DK2902035T3 (da) 2018-09-24
EP2627346A1 (en) 2013-08-21
PL2902035T3 (pl) 2019-04-30
EP2902035A1 (en) 2015-08-05
HK1210056A1 (en) 2016-04-15
EP2902035B1 (en) 2018-06-20
WO2012048893A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
US10967038B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
DK2627346T3 (da) Cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til anvendelse i behandling af uveitis
US20140309400A1 (en) Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome
AU2009253347B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
KR20080084937A (ko) 융합 폴리펩타이드를 세포로 전달하는 방법
KR20180132807A (ko) 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제
JP2018525337A (ja) 軽度認知障害の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用
US20180170983A1 (en) New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
ZA200600914B (en) Methods and compositions for treating disorders of the extracellular matrix
EP2785363A1 (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
AU2004253185A1 (en) Methods and compositions for treating disorders of the extracellular matrix